Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cipro Inhale · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cipro Inhale (Ciprofloxacin, BAYQ3939) | DRUG | 32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation |
Inclusion Criteria: * Adult subjects with COPD, 40 - 75 years of age * All subjects must have a diagnosis of COPD and must have airway obstruction with a post-bronchodilator Forced Expiratory Volume in 1 sec (FEV1) of \>/= 30% and \<= 80% of predicted and a post-bronchodilator FEV1 / Forced Vital C...
Top 20 of 28 competitors
Cipro Inhale is an investigational small molecule being developed for the treatment of infection. It is a ciprofloxacin inhalation powder intended for delivery directly to the lungs. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Cipro Inhale is being developed by Bayer AG, a pharmaceutical company traded under the ticker BAYRY. The drug is an inhaled formulation of ciprofloxacin, a small molecule antibiotic, and is currently in Phase 1 clinical development for the treatment of infections.
Cipro Inhale is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for the treatment of infection.
Cipro Inhale has one completed Phase 1 clinical trial, NCT01168895, which investigated the safety, tolerability, and pharmacokinetics of single-dose inhalations of 50 mg and 75 mg ciprofloxacin inhalation powder. The trial enrolled 12 participants, including healthy volunteers, and was conducted in Germany.
Cipro Inhale is an inhaled formulation of ciprofloxacin, a small molecule antibiotic. It is designed to deliver ciprofloxacin directly to the lungs via inhalation powder. The drug is being developed by Bayer AG and is currently in Phase 1 clinical development for the treatment of infection.